Lineage Cell Therapeutics Stock Probability Of Bankruptcy

BTX Stock  ILS 487.30  4.70  0.96%   
Lineage Cell's likelihood of distress is under 24% at this time. It has slight risk of undergoing some form of financial straits in the near future. Chance Of Bankruptcy shows the probability of financial distress over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Lineage balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Lineage Cell Piotroski F Score and Lineage Cell Altman Z Score analysis.
  

Lineage Probability Of Bankruptcy Analysis

Lineage Cell's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Lineage Cell Probability Of Bankruptcy

    
  Less than 24%  
Most of Lineage Cell's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lineage Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Lineage Cell probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Lineage Cell odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Lineage Cell Therapeutics financial health.
Please note, there is a significant difference between Lineage Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lineage Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lineage Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Lineage Cell Therapeutics has a Probability Of Bankruptcy of 24.0%. This is 44.56% lower than that of the Healthcare sector and 56.24% lower than that of the Biotechnology industry. The probability of bankruptcy for all Israel stocks is 39.74% higher than that of the company.

Lineage Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lineage Cell's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics of similar companies.
Lineage Cell is currently under evaluation in probability of bankruptcy category among related companies.

Lineage Fundamentals

About Lineage Cell Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lineage Cell in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lineage Cell's short interest history, or implied volatility extrapolated from Lineage Cell options trading.

Pair Trading with Lineage Cell

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lineage Cell position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lineage Stock

  0.78ENLV Enlivex TherapeuticsPairCorr

Moving against Lineage Stock

  0.49KTOV Purple BiotechPairCorr
  0.41PPBT Purple BiotechPairCorr
The ability to find closely correlated positions to Lineage Cell could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lineage Cell when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lineage Cell - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lineage Cell Therapeutics to buy it.
The correlation of Lineage Cell is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lineage Cell moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lineage Cell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lineage Cell can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:
Check out Lineage Cell Piotroski F Score and Lineage Cell Altman Z Score analysis.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Lineage Stock analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Valuation
Check real value of public entities based on technical and fundamental data
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Please note, there is a significant difference between Lineage Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lineage Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lineage Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.